Rapid nirmatrelvir treatment may reduce long COVID risk

By Elissa Wolfson, The Science Advisory Board assistant editor

March 24, 2023 -- A study of people with SARS-CoV-2 infection who had at least one risk factor for progression to severe disease found that treatment with nirmatrelvir within five days of a positive SARS-CoV-2 test result was associated with reduced risk of post−COVID-19 condition, known as long COVID. The findings, published Thursday in JAMA Internal Medicine, held true across the risk spectrum in this cohort, regardless of vaccination status and history of prior infection.

The prevention of long COVID, which affects many individuals, has become an urgent public health priority. Nirmatrelvir, an oral protease inhibitor, has demonstrated antiviral activity against all coronaviruses known to infect humans. Nirmatrelvir is currently packaged with ritonavir as Paxlovid for treating COVID-19 in higher-risk individuals. The researchers sought to examine whether treatment with nirmatrelvir in the acute phase of COVID-19 was associated with reduced long-COVID risk.

This cohort study used the health care databases of the U.S. Department of Veterans Affairs to identify patients who had a SARS-CoV-2 positive test result between January 3, 2022, and December 31, 2022, who were not hospitalized on the day of the positive test result, who had at least one risk factor for progression to severe COVID-19 illness, and who had survived 30 days following SARS-CoV-2 diagnosis. A total of 281,793 patients, mean age 61.9, of which 242,383 (86.01%) were male, were studied. Among them, 246,076 received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection, and 35,717 received oral nirmatrelvir within five days after the positive SARS-CoV-2 test result.

Inverse probability-weighted survival models were used to estimate the association of nirmatrelvir (versus control) with post-acute death, post-acute hospitalization, and a prespecified panel of 13 post-acute COVID-19 symptoms—all components of long COVID.

Compared with the control group, nirmatrelvir was associated with reduced long COVID risk, including reduced risk of 10 of 13 post-acute symptoms in the cardiovascular system (dysrhythmia and ischemic heart disease), coagulation and hematologic disorders (pulmonary embolism and deep vein thrombosis), fatigue and malaise, acute kidney disease, muscle pain, neurologic system issues (neurocognitive impairment and dysautonomia), and shortness of breath. Nirmatrelvir was also associated with reduced risk of post-acute death and post-acute hospitalization. In addition, nirmatrelvir was associated with reduced long-COVID risk in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection.

The researchers concluded that in people with SARS-CoV-2 infection and at least one risk factor for progression to severe COVID-19 illness, treatment with nirmatrelvir within five days of a positive SARS-CoV-2 test result — the acute phase of COVID-19 — reduces the risk of long COVID across the risk spectrum, regardless of vaccination status and history of prior infection.

Long COVID less likely after Omicron than after original virus, Swiss researchers find
Swiss researchers have found that the Omicron variant of SARS-CoV-2 is much less likely to lead to long COVID than the original wild-type virus circulating...
COVID-19 leads to increased chest pain long after infection
Researchers from Utah-based Intermountain Health, a not-for-profit system of hospitals, studied nearly 150,000 patients for cardiovascular symptoms following...
Collaborative research helps long-COVID patients recover
In the NIH Directors Blog posted on Wednesday, Dr. Gary Gibbons of the National Heart, Lung, and Blood Institute writes about a National Institutes...
Heart problems more likely among long COVID patients in comprehensive study
Individuals with long COVID were found to have more than double the risk of developing new cardiovascular symptoms. The results of a comprehensive study...
Paxlovid effective against Omicron subvariants in study
Colorado researchers investigated the effectiveness of the drug nirmatrelvir-ritonavir, also known as Paxlovid, in non-hospitalized patients during a...
Anixa Biosciences, MolGenie announce SARS-CoV-2 protease inhibitor
Anixa Biosciences and its partner MolGenie have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting the...
FDA authorizes Pfizer's COVID-19 pill
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for nirmatrelvir and ritonavir tablets (which are co-packaged for...

Copyright © 2023 scienceboard.net


Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter